Purchase this article with an account.
Eun Kyoung Lee, Jin Young Kim, Hyeong Gon Yu; Inhibition of Experimental Choroidal Neovascularization by Angiogenesis Inhibitor ALS-L1023. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4984.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
This study was undertaken to investigate the suppressing effects of orally administered botanical drug ALS-L1023 (ALS) on choroidal neovascularization (CNV) in a laser-induced rat model.
The CNV was induced by 577 nm diode laser photocoagulation in a total of 32 male Brown Norway rats. The ALS 50-, 100 mg/kg, or vehicle was administered orally starting at 3 days before and once daily after laser treatment. Fourteen days after laser treatment, spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA) were performed to evaluate size and leakage of CNV and eyes were enucleated for choroidal flat mounts and histologic evaluation.
Dimensions of CNV lesion including CNV area, CNV thickness, and CNV/choroid thickness ratio were significantly reduced in the ALS group, in a dose-dependent manner, compared with the control group (CNV area: 39,948.9 ± 9,811.8 µm2 vs. 28,959.7 ± 13,124.0 µm2 vs. 15,775.0 ± 5,687.3 µm2, P < 0.001; CNV thickness: 75.38 ± 6.39 µm vs. 66.33 ± 8.11 µm vs. 54.95 ± 5.23 µm, P < 0.001). The proportion of CNV lesions showing clinically significant fluorescein leakage was also lower in the ALS group compared with the control group (53.4% vs. 39.1% vs. 8.2%, P < 0.001).
Our data revealed that systemic administration of ALS suppressed laser-induced CNV formation in rats. Therefore, ALS may be clinically beneficial as a potential candidate drugs for the treatment of exudative age-related macular degeneration.
This PDF is available to Subscribers Only